SCHEDULE 13D/A 0001172898 XXXXXXXX LIVE 4 Common Stock, par value $0.0001 per share 03/10/2026 false 0001725255 00653Q102 AdaptHealth Corp.

555 EAST NORTH LANE, SUITE 5075 CONSHOHOCKEN PA 19428

Gregory Belinfanti (212) 277-1500 c/o One Equity Partners 510 Madison Avenue, 19th Floor New York NY 10022 Jeremy S. Liss (305) 432-5600 c/o Kirkland & Ellis LLP 98 S.E. 7th Street, Suite 700 Miami FL 33131 Ross M. Leff (212) 446-4800 c/o Kirkland & Ellis LLP 601 Lexington Avenue New York NY 10022 Jeremy S. Liss (312) 862-2000 c/o Kirkland & Ellis LLP 333 West Wolf Point Plaza Chicago IL 60654 Y OEP AHCO Investment Holdings, LLC b AF N DE 0 15864871 0 15864871 15864871 N 11.7 OO The reported percentage is calculated based on 135,914,816 shares of Common Stock, par value $0.0001 per share ("Common Stock") outstanding as of February 20, 2026, as reported in the Issuer's Annual Report on Form 10-K ("Form 10-K") filed with the SEC on February 24, 2026. Y One Equity Partners VII, L.P. b OO N E9 0 15864871 0 15864871 15864871 N 11.7 PN The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026. Y One Equity Partners VII-A, L.P. b OO N E9 0 15864871 0 15864871 15864871 N 11.7 PN The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026. Y One Equity Partners VII-B, L.P. b OO N DE 0 15864871 0 15864871 15864871 N 11.7 PN The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026. Y OEP VII Project A Co-Investment Partners, L.P. b OO N DE 0 15864871 0 15864871 15864871 N 11.7 PN The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026. Y OEP VII Project A-I Co-Investment Partners, L.P. b OO N DE 0 15864871 0 15864871 15864871 N 11.7 PN The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026. Y OEP VII General Partner, L.P. b AF N E9 0 15864871 0 15864871 15864871 N 11.7 PN The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026. 0001817118 N OEP VII GP, L.L.C. b AF N E9 0 15864871 0 15864871 15864871 N 11.7 OO The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026. 0001172898 N Richard Cashin b AF N X1 0 15864871 0 15864871 15864871 N 11.7 IN The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026. Common Stock, par value $0.0001 per share AdaptHealth Corp. 555 EAST NORTH LANE, SUITE 5075 CONSHOHOCKEN PA 19428 This Amendment No. 4 (this "Amendment") to Schedule 13D, which amends the Schedule 13D filed with the SEC on July 10, 2020 (the "Schedule 13D"), as amended by Amendment No. 1 (the "First Amendment") to Schedule 13D filed with the SEC on August 10, 2020, Amendment No. 2 (the "Second Amendment") to Schedule 13D filed with the SEC on August 24, 2020, and Amendment No. 3 (the "Third Amendment") to Schedule 13D filed with the SEC on August 31, 2020, is being filed by the Reporting Persons (as defined below) with respect to shares of Common Stock of the Issuer. Capitalized terms used herein but not defined have the meanings ascribed to them in the Schedule 13D, as amended by the First Amendment, Second Amendment, and Third Amendment. Item 2(a) of the Schedule 13D is hereby amended and restated as follows: This Amendment is filed jointly on behalf of the entities and persons described in this Item 2(a), all of whom are together referred to herein as the "Reporting Persons." (i) OEP AHCO Investment Holdings, LLC, a Delaware limited liability company ("Investor") (ii) One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP") (iii) One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP") (iv) One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP") (v) OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") (vi) OEP VII Project A-I Co-Investment Partners, L.P. , a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds") (vii) OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP") (viii) OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC") (ix) Richard Cashin Item 5(a) of the Schedule 13D is hereby supplemented as follows: The information set forth in rows (11) and (13) of the cover pages of this Schedule 13D is incorporated by reference into this Item 5. Ownership percentages set forth in this Schedule 13D assume 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026. As of the date hereof, each of the Reporting Persons may be deemed the beneficial owner of 15,864,871 shares of Common Stock, which represents approximately 11.7% of the total outstanding Common Stock. The reported securities are directly held by Investor. Investor is owned by the Parallel Funds. The general partner of each of the Parallel Funds is OEP VII GP, and the general partner of OEP VII GP is OEP VII GP LLC. The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Neither the filing of this statement nor any of its contents shall be deemed to constitute an admission by any of the Reporting Persons that such person is the beneficial owner of any shares of Common Stock referred to herein for purposes of the Act, or for any other purpose. Item 5(b) of the Schedule 13D is hereby supplemented as follows: The information set forth in rows (7) through (10) of the cover pages of this Schedule 13D is incorporated by reference into this Item 5. Item 5(c) of the Schedule 13D is hereby supplemented as follows: Within the prior 60 days, the Reporting Persons acquired shares of Common Stock in the market transactions set forth in Exhibit 7 attached hereto. Not applicable. Not applicable. Exhibit 1 of Item 7 of the Schedule 13D is hereby amended and restated and Item 7 is hereby supplemented as follows: Exhibit 1 Joint Filing Agreement, dated March 12, 2026. Exhibit 6 Signature Page, dated March 12, 2026. Exhibit 7 Transactions by the Reporting Persons. OEP AHCO Investment Holdings, LLC /s/ Gregory Belinfanti 03/12/2026 One Equity Partners VII, L.P. /s/ Gregory Belinfanti 03/12/2026 One Equity Partners VII-A, L.P. /s/ Gregory Belinfanti 03/12/2026 One Equity Partners VII-B, L.P. /s/ Gregory Belinfanti 03/12/2026 OEP VII Project A Co-Investment Partners, L.P. /s/ Gregory Belinfanti 03/12/2026 OEP VII Project A-I Co-Investment Partners, L.P. /s/ Gregory Belinfanti 03/12/2026 OEP VII General Partner, L.P. /s/ Gregory Belinfanti 03/12/2026 OEP VII GP, L.L.C. /s/ Gregory Belinfanti 03/12/2026 Richard Cashin /s/ Richard Cashin 03/12/2026